Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2021
Date Filed: December 09, 2021
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory notifications rather than financial performance data.
Material Changes
The filing does not disclose material changes in financial position or operations compared to prior periods. The primary content is the submission of Exhibit 99.1 regarding unquoted securities.
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Guidance/Outlook: Not applicable.
Risks/Contingencies: The filing incorporates by reference into Registration Statements on Form S-8 and Form F-3. It includes a notification regarding unquoted securities (Exhibit 99.1), but specific risk factors are not detailed in this text.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 ("Notification regarding unquoted securities") for details on the specific securities transaction.
- Verify the status of the referenced Registration Statements (Form S-8 and Form F-3) to understand the context of the incorporation by reference.
- Confirm the company's current cash runway and burn rate in subsequent filings, as this 6-K does not contain financial statements.
- Check for any updates on the company's development stage status and clinical trial progress in other recent disclosures.